Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 23, 2026

New Crypto: Pepeto Presale Stage Update While Dogecoin Price Prediction Heats Up After Elon Musk Dogefather Post and Shiba Inu Pattern Returns

View original at globenewswire.com
New Crypto: Pepeto Presale Stage Update While Dogecoin Price Prediction Heats Up After Elon Musk Dogefather Post and Shiba Inu Pattern Returns Dubai, UAE, March 22, 2026 (GLOBE NEWSWIRE) -- Pepeto confirms the fund just passed $8.28 million after the sell out of the last stage, this new crypto presale is filling faster…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The dogecoin price prediction for $1 requires $140 billion market cap which analysts say Dogecoin cannot hold without utility

    60% confidence

  • Pepeto's exchange runs a zero fee execution layer with native cross chain settlement and AI contract scanning across Ethereum, BNB Chain, and Solana, giving the meme coin market trading tools it never had before

    60% confidence

  • There are some Elon Musk connections to Pepeto growing across crypto communities now, adding the same attention that made Dogecoin explode

    60% confidence

  • Pepeto offers presale entry into a verified DeFi exchange with viral community demand, making it the new crypto that Shiba Inu and Dogecoin investors wish existed at this stage

    60% confidence

  • Every bull market in crypto produces new millionaires, and they almost always come from the same place: meme coin presales that hit at the right time

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
New Crypto: Pepeto Presale Stage Update While Dogecoin Price Prediction Heats Up After Elon Musk Dogefather Post and Shiba Inu Pattern Returns — Source | Via News | ViaNews EU